Vigilancia activa del cáncer de próstata

Bill-Axelson, 2018, Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up, N Engl J Med, 379, 2319, 10.1056/NEJMoa1807801 Wilt, 2020, Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT), Eur Urol, 77, 713, 10.1016/j.eururo.2020.02.009 Klotz, 2010, Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer, J Clin Oncol, 28, 126, 10.1200/JCO.2009.24.2180 Hardie, 2005, Early outcomes of active surveillance for localized prostate cancer, BJU Int, 95, 956, 10.1111/j.1464-410X.2005.05446.x Donovan, 2016, Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer, N Engl J Med, 375, 1425, 10.1056/NEJMoa1606221 Hamdy, 2016, 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Ploussard, 2010, The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number, BJU Int, 106, 1293, 10.1111/j.1464-410X.2010.09361.x Cornu, 2012, Evolution of the landscape of surgical management of prostate cancer in France: the case of radical prostatectomy, Eur Urol, 62, 735, 10.1016/j.eururo.2012.06.053 Klotz, 2015, Long-term follow-up of a large active surveillance cohort of patients with prostate cancer, J Clin Oncol, 33, 272, 10.1200/JCO.2014.55.1192 Eggener, 2013, A multi-institutional evaluation of active surveillance for low risk prostate cancer, J Urol, 189, S19 Bul, 2013, Active surveillance for low-risk prostate cancer worldwide: the PRIAS study, Eur Urol, 63, 597, 10.1016/j.eururo.2012.11.005 Godtman, 2013, Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial, Eur Urol, 63, 101, 10.1016/j.eururo.2012.08.066 Dall’Era, 2008, Active surveillance for the management of prostate cancer in a contemporary cohort, Cancer, 112, 2664, 10.1002/cncr.23502 Selvadurai, 2013, Medium-term outcomes of active surveillance for localised prostate cancer, Eur Urol, 64, 981, 10.1016/j.eururo.2013.02.020 Carter, 2007, Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience, J Urol, 178, 2359, 10.1016/j.juro.2007.08.039 Tosoian, 2011, Active surveillance program for prostate cancer: an update of the Johns Hopkins experience, J Clin Oncol, 29, 2185, 10.1200/JCO.2010.32.8112 Gandaglia, 2018, How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator, BJU Int, 122, 823, 10.1111/bju.14391 Iremashvili, 2012, Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols, Eur Urol, 62, 462, 10.1016/j.eururo.2012.03.011 Ploussard, 2009, The role of biopsy core number in selecting prostate cancer patients for active surveillance, Eur Urol, 56, 891, 10.1016/j.eururo.2009.07.053 Mottet, 2017, EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 71, 618, 10.1016/j.eururo.2016.08.003 Balakrishnan, 2019, Evaluating the safety of active surveillance: outcomes of deferred radical prostatectomy after an initial period of surveillance, J Urol, 202, 506, 10.1097/JU.0000000000000247 Ploussard, 2011, Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance, Eur Urol, 59, 422, 10.1016/j.eururo.2010.11.044 Tosoian, 2010, Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program, J Urol, 183, 534, 10.1016/j.juro.2009.10.003 Bul, 2012, Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study, Eur Urol, 62, 195, 10.1016/j.eururo.2012.02.002 Amin, 2020, The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies, J Urol, 203, 910, 10.1097/JU.0000000000000693 Osses, 2020, Prostate cancer upgrading with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?, BJU Int, 126, 124, 10.1111/bju.15065 Moore, 2017, Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force, Eur Urol, 71, 648, 10.1016/j.eururo.2016.06.011 Lam, 2019, EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localized Prostate Cancer from an International Collaborative Study (DETECTIVE Study), Eur Urol, 76, 790, 10.1016/j.eururo.2019.09.020 Rozet, 2018, Recommandations françaises du Comité de cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate [French ccAFU guidelines - Update 2018-2020: Prostate cancer] [retraction of: Prog Urol 2018;28(Suppl. 12):S79-S130], Prog Urol, 28, R81-R132 Bratt, 2019, The value of an extensive transrectal repeat biopsy with anterior sampling in men on active surveillance for low-risk prostate cancer: a comparison from the Randomised Study of Active Monitoring in Sweden (SAMS), Eur Urol, 76, 461, 10.1016/j.eururo.2019.02.035 Klotz, 2020, Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up, Eur Urol, 77, 311, 10.1016/j.eururo.2019.10.007 Filippou, 2015, Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer, Eur Urol, 68, 458, 10.1016/j.eururo.2015.06.011 van den Bergh, 2010, Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?, Cancer, 116, 1281, 10.1002/cncr.24882 Ornish, 2013, Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study, Lancet Oncol, 14, 1112, 10.1016/S1470-2045(13)70366-8 Fleshner, 2012, Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial, Lancet, 379, 1103, 10.1016/S0140-6736(11)61619-X Tosoian, 2020, Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort, Eur Urol, 77, 675, 10.1016/j.eururo.2019.12.017 Carlsson, 2020, Long-term outcomes of active surveillance for prostate cancer: The Memorial Sloan Kettering Cancer Center Experience, J Urol, 203, 1122, 10.1097/JU.0000000000000713